PTC Therapeutics director sells 15,834 shares

PTC Therapeutics director Mary L. Smith exercised stock options for 15,834 shares of common stock at an exercise price of $42.95 per share and sold 15,834 shares in open-market transactions at $90.00 per share on July 9, 2026.

Rhea-AI Filing Summary

PTC Therapeutics director Mary L. Smith exercised stock options for 15,834 shares of common stock at an exercise price of $42.95 per share and sold 15,834 shares in open-market transactions at $90.00 per share on July 9, 2026. The sales were effected pursuant to a written Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, she holds 21,813 shares of PTC Therapeutics common stock directly.

Filing Explained

Completed option exercises and matching sales left the reporting person with 21,813 direct shares under a pre-adopted Rule 10b5-1 plan.

The July 13 Form 4 reports that a director of PTC Therapeutics completed two option exercises on July 9, 2026, followed by sales of the same respective numbers of common shares.

The structural consequence is confined to the reporting person's disclosed holdings: 21,813 common shares remained held directly after the reported transactions.

The two options, each exercisable at $42.95, were exercised for 10,000 and 5,834 shares, respectively, and both option balances became zero.

Both sales were reported at $90 per share, and the filing says the transactions were effected under a written Rule 10b5-1 plan adopted on November 11, 2025.

For this form, M identifies an option or derivative exercise and S an open-market sale; the plan disclosure states its adoption date, not the reasons for individual trades.

Insider Trade Summary 10b5-1

Exercise and Sale: 15,834 shares ($745K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Smith Mary L.

Role Director

Sold 15,834 shs ($1.43M)

Approx. gross sale proceeds $1.43M

Approx. exercise cost $680K

Approx. pre-tax spread $745K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F2	10,000	$0.00	$0.00
Exercise	Stock Option (Right to Buy) F1, F2	5,834	$0.00	$0.00
Exercise	Common Stock F1	10,000	$42.95	$430K
Sale	Common Stock F1	10,000	$90.00	$900K
Exercise	Common Stock F1	5,834	$42.95	$251K
Sale	Common Stock F1	5,834	$90.00	$525K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 21,813 shares (Direct)

Footnotes (2)

1. F1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025.
2. F2. Currently exercisable.

Key Figures

Shares sold: 15,834 shares Sale price: $90.00 per share Option exercise shares: 15,834 shares +4 more

7 metrics

Shares sold 15,834 shares Total common shares sold in open-market transactions on July 9, 2026

Sale price $90.00 per share Price for common stock sales on July 9, 2026

Option exercise shares 15,834 shares Common shares acquired through stock option exercises on July 9, 2026

Option exercise price $42.95 per share Exercise or conversion price of stock options into common stock

Shares held after transactions 21,813 shares Direct ownership of PTC Therapeutics common stock after July 9, 2026 trades

Net buy/sell shares 15,834 shares Net-sell shares reported in transaction summary for this Form 4

Option expiration date June 10, 2031 Expiration date for the stock options exercised on July 9, 2026

Key Terms

Rule 10b5-1 plan, Stock Option (Right to Buy, derivative security, open-market sale

4 terms

Rule 10b5-1 plan regulatory

"This transaction was effected pursuant to a written Rule 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Stock Option (Right to Buy financial

"security_title: Stock Option (Right to Buy)"

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PTC Therapeutics (PTCT) director Mary L. Smith report in this Form 4?

Mary L. Smith reported exercising options for 15,834 shares of PTC Therapeutics common stock at $42.95 per share and selling 15,834 shares at $90.00 per share on July 9, 2026, in open-market transactions.

How many PTC Therapeutics (PTCT) shares did Mary L. Smith sell and at what price?

She sold a total of 15,834 shares of PTC Therapeutics common stock in open-market transactions at a price of $90.00 per share, according to the Form 4 transaction data for July 9, 2026.

What stock options did Mary L. Smith exercise in PTC Therapeutics (PTCT)?

She exercised stock options covering 15,834 shares of PTC Therapeutics common stock with an exercise price of $42.95 per share, described as an exercise or conversion of a derivative security on July 9, 2026.

How many PTC Therapeutics (PTCT) shares does Mary L. Smith own after these transactions?

After the reported transactions, Mary L. Smith directly holds 21,813 shares of PTC Therapeutics common stock, as indicated by the total shares following transaction field for her non-derivative holdings.

Were Mary L. Smith’s PTC Therapeutics (PTCT) stock sales under a Rule 10b5-1 plan?

Yes. A footnote states that the transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Mary L. Smith on November 11, 2025, indicating the trades were pre-arranged under that plan.

What is the net effect of Mary L. Smith’s July 9, 2026 trades in PTC Therapeutics (PTCT)?

The Form 4 summary shows 15,834 shares sold and 15,834 shares exercised, resulting in net-sell shares of 15,834 when considering open-market transactions versus exercises, with remaining direct ownership of 21,813 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 05:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Mary L.

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		M(1)		10,000	A	$42.95	31,813	D
Common Stock	07/09/2026		S(1)		10,000	D	$90	21,813	D
Common Stock	07/09/2026		M(1)		5,834	A	$42.95	27,647	D
Common Stock	07/09/2026		S(1)		5,834	D	$90	21,813	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$42.95	07/09/2026		M(1)			10,000	(2)	06/10/2031	Common Stock	10,000	$0	0	D
Stock Option (Right to Buy)	$42.95	07/09/2026		M(1)			5,834	(2)	06/10/2031	Common Stock	5,834	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025.

2. Currently exercisable.

	/s/ Avraham S. Adler, Attorney-in-Fact	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)